loading page

The potential value of Cancer-testis antigens in ovarian cancer: prognostic markers and targets for immunotherapy
  • +5
  • Lina Lin,
  • Xiaoqiong Zou,
  • Weixia Nong,
  • Yingying Ge,
  • Feng Li,
  • Bin Luo,
  • Qingmei Zhang,
  • Xiaoxun Xie
Lina Lin
Guangxi Medical University
Author Profile
Xiaoqiong Zou
Guangxi Medical University
Author Profile
Weixia Nong
Guangxi Medical University
Author Profile
Yingying Ge
Guangxi Medical University
Author Profile
Feng Li
Guangxi Medical University
Author Profile
Bin Luo
Guangxi Medical University
Author Profile
Qingmei Zhang
Guangxi Medical University
Author Profile
Xiaoxun Xie
Guangxi Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Tumor immunotherapy has become an important adjuvant therapy after surgery, radiotherapy, and chemotherapy. In recent years, the role of tumor-associated antigen (TAA) in tumor immunotherapy has become increasingly prominent. Cancer-testis antigen (CTA) is a kind of TAA that is highly restricted in a variety of tumors and can induce an immune response. The expression of CTA affects the occurrence, development, and prognosis of ovarian cancer and is closely related to tumor immunity. This review outlines a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTA in ovarian cancer, all of which can provide novel insights in the improvement of diagnosis and treatment for ovarian cancer.